NCT06511791 - An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta at Different Time Intervals During Controlled Ovarian Stimulation. | Biotech Hunter

Enrollment

106

Participants

Timeline

Start Date

July 15, 2024

Primary Completion Date

September 5, 2025

Study Completion Date

September 5, 2025

Conditions

Infertility

Interventions

DRUG

FE 999302

Effect on parameters influencing pregnancy rates when administered during different time intervals in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol

DRUG

Follitropin delta

The effect on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin.

DRUG

Placebo FE 999302

No active ingredient, subcutaneous injection.

Trial Locations (15)

1090

Ferring Investigational Site, Brussels

2100

Ferring Investigational Site, Copenhagen

2650

Ferring Investigational Site, Edegem

Ferring Investigational Site, Hvidovre

3913

Ferring Investigational Site, Porsgrunn

5006

Ferring Investigational Site, Bergen

7042

Ferring Investigational Site, Trondheim

16000

Ferring Investigational Site, Prague

28010

Ferring Investigational Site, Madrid

28023

Ferring Investigational Site, Madrid

41092

Ferring Investigational Site, Seville

46015

Ferring Investigational Site, Valencia

150 00

Ferring Investigational Site, Prague

184 00

Ferring Investigational Site, Prague

08028

Ferring Investigational Site, Barcelona